Risk of seizure recurrence after a first unprovoked seizure in childhood

Yuichi Takami1, Taku Nakagawa1

  • 1Department of Pediatrics, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.

Brain & Development
|May 18, 2021
PubMed

Insights

Over half of children experienced seizure recurrence after a first unprovoked seizure. However, prognosis remained good overall for these pediatric epilepsy patients.

Area of Science:

  • Pediatric Neurology
  • Epilepsy Research
  • Clinical Neurophysiology

Background:

  • First unprovoked seizures in children are common, with recurrence posing a significant concern.
  • Understanding recurrence risk factors is crucial for appropriate management and prognosis.

Purpose of the Study:

  • To evaluate the risk of seizure recurrence following a first unprovoked seizure in children.
  • To identify factors correlating with seizure recurrence and analyze the relationship between first and second seizures.

Main Methods:

  • A prospective study included 467 children (1 month–16 years) with a first seizure, excluding those on antiepileptic drugs.
  • Kaplan-Meier survival analysis calculated recurrence rates.
  • Cox proportional hazards models and kappa coefficient assessed recurrence risk and correlations.

Main Results:

  • Recurrence occurred in 60% of children, with 91.4% of recurrences happening within 2 years.
  • Estimated recurrence risks were 39.5% at 6 months and 61.8% at 10 years.
  • Abnormal EEG and neuroimaging significantly increased recurrence risk; first/second seizures correlated with arousal state, status epilepticus, and multiple seizures.

Conclusions:

  • More than half of untreated children experienced recurrence after a first unprovoked seizure.
  • Despite high recurrence rates, the overall prognosis for these children was favorable.
  • Abnormal EEG and neuroimaging are key predictors of recurrence in pediatric epilepsy.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
860
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
632
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
570
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
398
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
885
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.2K